FDA Approves New Oral Combination Treatment for Common Breast Cancer Mutation

In a significant advancement for breast cancer care, the U.S. Food and Drug Administration (FDA) has approved a new oral combination therapy for patients with a specific mutation associated with advanced breast cancer. The approval, granted on September 18, allows the use of two medications—Inluriyo (imlunestrant) and Verzenio (abemaciclib)—together for adults diagnosed with estrogen receptor-positive (ER-positive), HER2-negative advanced or metastatic breast cancer that has an ESR1 mutation.

This approval is particularly relevant for patients whose cancer has progressed following hormone therapy. The clinical trial data indicated that individuals taking the combination therapy experienced a median of 11.1 months before their cancer worsened or they passed away, significantly longer than the 5.5 months for those who were treated with Inluriyo alone.

Inluriyo works by blocking estrogen signaling in breast cancer cells and aiding in the breakdown of estrogen receptors, while Verzenio inhibits proteins that drive cancer cell growth and division. The combination of these two treatments represents a new approach for managing this challenging form of breast cancer.

Dr. Neil Iyengar, a breast medical oncologist at Winship Cancer Institute of Emory University, noted that while the individual medications are not new, their combined use is a fresh concept that is now officially endorsed by the FDA. Dr. Komal Jhaveri from Memorial Sloan Kettering Cancer Center, who led the clinical trial, emphasized that this approval facilitates easier access to a treatment regimen that many oncologists were already prescribing off-label.

### Eligibility Criteria

The combination therapy is specifically approved for adults who meet several criteria: their cancer must be locally advanced or metastatic, ER-positive, HER2-negative, confirmed to have an ESR1 mutation through FDA-authorized testing, and must have shown growth after at least one round of hormone therapy.

### Understanding ESR1 Mutations

ESR1 mutations are significant in breast cancer, as they alter estrogen receptors in a way that can enable cancer to resist hormone therapy. While these mutations are present in about 1% of breast tumors at diagnosis, they occur in 10% to 50% of metastatic cancers that stop responding to treatment.

### Advantages of Combination Therapy

Prior to this approval, patients with ESR1 mutations typically switched to other hormone therapies when their initial treatments failed. The new dual therapy allows for targeted treatment to continue, potentially extending patient survival and improving quality of life. This is a departure from older treatments, which often required painful injections of fulvestrant.

### Side Effects and Safety Considerations

In the clinical trials, common side effects of the combination therapy included diarrhea, which affected 86% of participants, with 9% experiencing severe cases. Other potential side effects include low white blood cell counts, liver problems, lung inflammation, and blood clots. Medical professionals will monitor patients closely for any adverse reactions.

### Testing for ESR1 Mutations

To determine eligibility for this new treatment, a blood test can identify the presence of ESR1 mutations. The FDA has approved tests like Guardant360 CDx, which can help clinicians determine the best course of action for patients with metastatic breast cancer.

As researchers continue to explore the efficacy of Inluriyo and Verzenio in various settings, including early-stage breast cancer, there is optimism in the field. The recent FDA approval marks a promising step forward in enhancing treatment options for patients facing this